Santarus appoints Wendell Wierenga executive vice-president
This article was originally published in Scrip
Santarus, a speciality biopharmaceutical company, has appointed Dr Wendell Wierenga executive vice-president of R&D. In this role, Dr Wierenga will oversee clinical research, regulatory affairs, quality assurance, medical affairs and pharmacovigilance. He was previously executive vice-president of R&D for Ambit Biosciences Corporation, and currently serves on the boards of Cytokinetics, Onyx Pharmaceuticals and XenoPort.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.